Colistimethate Sodium PCD Pharma Franchise Company

Cafoli Lifecare offers a Colistimethate Sodium range of 4 injection formulations, manufactured in WHO-GMP certified facilities. Distributors supplying hospitals and critical-care units can secure district-wise monopoly franchise rights on this reserve-line antibiotic.

What is Colistimethate Sodium?

Colistimethate sodium is the prodrug of colistin, a polymyxin antibiotic that disrupts the outer membrane of Gram-negative bacteria. It is reserved for serious multidrug-resistant Gram-negative infections and is listed on the WHO Model List of Essential Medicines. Compound details are available on PubChem.

Therapeutic Applications

Colistimethate sodium is used intravenously and by nebulisation for multidrug-resistant infections caused by Pseudomonas, Acinetobacter and carbapenem-resistant Enterobacteriaceae, including hospital-acquired pneumonia and ventilator-associated pneumonia. Prescribers are intensivists, pulmonologists, nephrologists and infectious-disease specialists.

Why Colistimethate Sodium is a High-Potential Molecule for Distributors

Antimicrobial resistance is rising rapidly in Indian ICUs, and colistin is one of the few remaining agents effective against carbapenem-resistant Gram-negative pathogens. Its status as a reserved, high-value injectable drives steady hospital tender demand with limited competition, making it an attractive high-margin institutional line for partners with a hospital-supply footprint.

Why Choose Cafoli Lifecare

Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.

References

1. PubChem: Colistimethate Sodium
2. WHO Model List of Essential Medicines